Evidence Summaries
Evidence Summaries
Evidence Summaries
There is no direct evidence that aciclovir has a beneficial effect on outcomes in Ramsay Hunt syndrome (herpes zoster oticus, HZO, associated with acute facial paralysis), although the use of aciclovir in patients with HZ in other parts of the body suggest that they have a role also in HZO.
A Cochrane review 1 included 1 low-quality study with a total of 15 subjects. All participants received intravenous corticosteroids (methylprednisolone 20 mg/8 hours for 10 days). Seven participants only received this treatment (control group) whilst eight (the treatment group) received in addition intravenous acyclovir (10 mg/kg/8h for 10 days). No statistically significant difference between the two groups was found.
Comment: The quality of evidence is downgraded by imprecise results (very few patients and wide confidence intervals) and by study quality (lack of blinding).
References
References
References
1. Uscategui T, Dorée C, Chamberlain IJ, Burton MJ. Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008 Oct 8;(4):CD006851.
[PMID:18843734] Copyright © 2023 Duodecim Medical Publications Limited.
TY - ELEC
T1 - Aciclovir for Ramsay Hunt syndrome
ID - 455861
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455861/all/Aciclovir_for_Ramsay_Hunt_syndrome
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -